Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialIndividualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresNucleic acid targeting: towards personalized therapy for head and neck cancer.Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerThe role of systemic treatment before, during, and after definitive treatmentCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaNanotechnology-based drug delivery systems for treatment of oral cancer: a reviewNovel immunotherapeutic strategies of gastric cancer treatmentHER2 as a therapeutic target in head and neck squamous cell carcinomaImpact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyAn update on larynx cancer1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapyLow-intensity ultrasound enhances the anticancer activity of cetuximab in human head and neck cancer cellsThe MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data.Antibody Therapies in Cancer.Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyPhase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckReversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody TherapyRationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapyA pathway-based classification of human breast cancer.The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.Targeting CD137 enhances the efficacy of cetuximab.Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data.Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaTargeting the epidermal growth factor receptor for head and neck cancer chemopreventionPrognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapyAn effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
P2860
Q21198850-E850860F-08DA-4630-AD45-FED4340A6A42Q24652337-ECFAEC3C-0842-4E95-8922-0DD75E19BD65Q26750719-2E1F2348-825F-4340-930F-97088447A12DQ26769884-DCB7DF69-2764-4522-B4E7-783B048312B7Q26776198-D3A830A6-7988-4A89-BF7B-9AE97F53E399Q26850237-0A6754FC-85BF-4160-9910-37D8B4135678Q26852215-BD94EB60-0AC5-464B-A2C2-B66B67F2E799Q26859285-57BB43BF-7E82-4385-8A16-C3774C1C8484Q26991953-C92A92CB-E9BB-4494-B721-0006EEA0E660Q26995835-B93B52E3-0262-455A-997B-E2CD7726B8B2Q27011232-6A5F4EF6-134D-43E3-B46C-8ABEC67F94CEQ27026178-4604A156-DD87-49C3-B9F6-0CDB224FF827Q27852901-7C11D9F3-1C42-449C-AEF8-D801A24578BDQ28079132-392A1CC5-582A-4FC5-93E0-EAEDDC891D36Q28476652-D344C94B-CCD4-4529-AB9A-C11C261366C3Q30459812-9DEA6799-B60C-4DDA-A1A8-F6ED0942ED1DQ30494514-277D4CE4-7A68-4BE5-B7AE-7403DB9850D2Q30557865-9E9A2BF2-4286-4201-ACA7-5304F9FFBA4FQ30919257-73411513-37E1-47B3-833E-106A38BBF427Q31104000-26DCB871-80E7-42D4-9F80-E60428C7817AQ33383131-EF2388FB-D018-4F73-8AA1-365FC12EC6D8Q33401499-E28EE139-C709-4512-9779-DD0A2FA12F47Q33406802-F9ADBE8A-C5F1-4211-9AE8-D426ABAD0863Q33434648-2866EFF6-EBC7-4118-AC0E-C8505CE5BB3FQ33436548-B5990903-B661-4CC7-8925-998C0710C31FQ33609291-BF42DE53-316B-4FD4-AC0B-170F034D81E3Q33650470-D1F9478B-9303-484D-B30F-25551E1C0696Q33736664-13DD6966-A9BE-410F-9D75-69519E5CD2D6Q33839177-B978B52B-25A2-479C-904F-FEF91FCCF5E1Q33859531-1D53ABBE-1450-41FC-92FC-40F6C92A0106Q33865354-54AAFDD4-D0DC-4B9B-834A-5CDB16B34A0EQ33872482-3F22C882-6573-4466-918A-5E84D7D0696FQ33873118-72FAED74-F438-4450-871E-23A5F7349D53Q33875560-E8A8D91E-72ED-453B-BD37-5116D00E77AAQ33875694-97D7A835-015D-4202-9FAE-CB7D4F60F393Q33884484-027F7492-873E-4B5E-83B2-A67D230A21E2Q33895284-BBEB85C3-D0F6-45FF-895D-62AAA718E8F3Q33898889-011CA99B-4823-4966-B5C3-C7F03D572023Q33916035-F92519B4-C8EB-4444-95F6-6D7827D60A39Q33941497-65E436D6-9EBB-4EC4-9FD4-D24405302DD4
P2860
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base
description
article
@en
im Juni 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2007
@uk
name
Open-Label, Uncontrolled, Mult ...... ed to Respond to Platinum-Base
@en
Open-Label, Uncontrolled, Mult ...... ed to Respond to Platinum-Base
@nl
type
label
Open-Label, Uncontrolled, Mult ...... ed to Respond to Platinum-Base
@en
Open-Label, Uncontrolled, Mult ...... ed to Respond to Platinum-Base
@nl
prefLabel
Open-Label, Uncontrolled, Mult ...... ed to Respond to Platinum-Base
@en
Open-Label, Uncontrolled, Mult ...... ed to Respond to Platinum-Base
@nl
P2093
P356
P1476
Open-label, uncontrolled, mult ...... pond to platinum-based therapy
@en
P2093
Armin Schueler
Jan B Vermorken
José Baselga
José Trigo
Nadia Amellal
Piotr Koralewski
Rainald Knecht
Ricardo Hitt
P304
P356
10.1200/JCO.2006.06.7447
P407
P577
2007-06-01T00:00:00Z